Phase I/II open-label trial of intravenous allogeneic mesenchymal stromal cell therapy in adults with recessive dystrophic epidermolysis bullosa - Concepedia

Concepedia

Publication | Open Access

Phase I/II open-label trial of intravenous allogeneic mesenchymal stromal cell therapy in adults with recessive dystrophic epidermolysis bullosa

DOI Full Paper Access

109

Citations

21

References

2019

Year

Ellie Rashidghamat, Tendai Kadiyirire, Salma Ayis, Gabriela Petrof, Lu Liu, Venu Pullabhatla, Chrysanthi Ainali, Alyson Guy, Sophia Aristodemou, James R. McMillan,

Journal of the American Academy of Dermatology

Abstract

MSC infusion is safe in RDEB adults and can have clinical benefits for at least 2 months.

References

	Year	Citations

Page 1